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Gpbar1 (TGR5), a membrane-bound bile acid receptor, is well-known for its roles
in regulation of energy homeostasis and glucose metabolism. Here, we show
that mice lacking TGR5 were much more susceptible to lipopolysaccharide
(LPS)-induced acute gastric inflammation than wild-type (WT) mice and TGR5 is
a negative regulator of gastric inflammation through antagonizing NF-κB signaling
pathway. We found that the treatment of TGR5 ligands 23(S)-mCDCA and
GPBARA (3-(2-Chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethylisoxazole-4-carboxamide)
suppressed gene and protein expression mediated by NF-κB signaling. TGR5
overexpression with ligand treatment inhibited gene expression of interferon-inducible
protein 10 (IP-10), TNF-α, and chemoattractant protein-1 (MCP-1) induced by LPS.
Furthermore, we revealed that TGR5 activation antagonized NF-κB signaling pathway
through suppressing its transcription activity, the phosphorylation of IκBα and p65
translocation, which suggests that TGR5 antagonizes gastric inflammation at least in
part by inhibiting NF-κB signaling. These findings identify TGR5 as a negative mediator
of gastric inflammation that may serve as an attractive therapeutic tool for human gastric
inflammation and cancer.
Keywords: tgr5, GPBAR1, GPCR, NF-κB, gastric inflammation
INTRODUCTION
Chronic inflammation is increasingly recognized as an important tumor promoter (Pikarsky et al.,
2004; Yoshizaki et al., 2010). The precise control of inflammation is essential for the prevention
of chronic inflammatory disorders, as well as for inhibiting the exacerbation or progression of
diseases, including many types of cancers. Gastric cancer is an inflammation-associated cancer
because Helicobacter pylori, which infects 50% of the world’s population, is now known to be
responsible for inducing chronic gastric inflammation that progresses to atrophy, metaplasia,
dysplasia, and gastric cancer (Fox and Wang, 2007). Thus, the control of gastric inflammation is
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important for the prevention and treatment of gastric cancer
(Karin and Greten, 2005; Hotamisligil, 2008).
Activated NF-κB is frequently detected in various
inflammatory diseases and tumors. The activation of NF-
κB is one of the critical cellular responses to acute infections
and inflammations (Aggarwal, 2004; Karin and Greten, 2005).
So NF-κB has received extensive attention as a key regulator
of inflammation and carcinogenesis (Pikarsky et al., 2004; Fox
and Wang, 2007). In response to lipopolysacchride (LPS) or
pro-inflammatory cytokines, NF-κB can be rapidly activated.
Pikarsky et al. and Greten et al. reported that the classical, IKK-
dependent NF-κB-activation pathway is a crucial mediator of
tumor progression (Greten et al., 2004; Pikarsky et al., 2004). The
classic form of NF-κB is the heterodimer of the p65/RelA and p50
subunits. It is activated in response to various stimuli, including
LPS, TNF-α, double-stranded RNA, and ultra-violet radiation.
Under normal conditions, NF-κB signaling are tightly controlled
by multiple negative feedback mechanisms. Conversely, chronic
activation of NF-κB signaling is frequently detected in numerous
human inflammatory diseases and cancer, including gastric
tumorigenesis (Hedvat et al., 2009; Lu et al., 2014; Yang et al.,
2015). Thus, constitutive NF-κB activation is fundamental to the
pathobiology of gastric cancer (D’Acquisto and Ianaro, 2006;
Lu et al., 2014). Therefore, defining new therapeutic targets that
inhibit prolonged activation of NF-κB signaling is crucial for
further understanding the regulation of this signaling pathway
and the development of novel therapeutic strategies to improve
disease symptoms in gastric inflammation and cancer (Israel
et al., 2001; Fox and Wang, 2007).
TGR5, as a bile acid membrane receptor, can regulate bile
acid homeostasis, energy homeostasis, and glucose metabolism
(Kawamata et al., 2003). It belongs to a member of the G-
protein-coupled receptor (GPCR) family which contains seven
transmembrane domains and transduces extracellular signals
through heterotrimeric G proteins (Duboc et al., 2014). We
and other group reported that TGR5 is a negative modulator
of NF-κB-mediated liver inflammation. TGR5 activation
suppressed NF-κB-mediated liver inflammation through
inhibiting phosphorylation of IκBa and nuclear translocation
of p65 in vitro and in vivo (Hedvat et al., 2009; Wang et al.,
2011). Helicobacter pylori infection upregulates NF-κB to induce
inflammation in the stomach (Yang et al., 2012). Chronic
inflammation is a frequent cause of cancer (Fox and Wang,
2007; Zhang et al., 2014). Disrupting the aberrant activation
of NF-κB signaling is able to dramatically suppress tumor
progression (Lu et al., 2014). Therefore, the previous results raise
the possibility that TGR5 may be a negative regulator of gastric
inflammation possibly through antagonizing NF-κB signaling in
stomach.
In this study, we show that TGR5 activation suppresses LPS-
induced gastric inflammation in vitro and in vivo. Furthermore,
we identified that TGR5 is a negative regulator of NF-κB
signaling pathways in gastric cancer cells via suppressing its
transcription activity, the phosphorylation of IκBα and p65
translocation, respectively. These findings suggest TGR5 may be
a potential target for therapeutic intervention in human gastric
inflammation through antagonizing NF-κB signaling.
MATERIALS AND METHODS
Reagents and Plasmids
Lipopolysaccharide (LPS, from Escherichia coli 0111:B4) was
purchased from Sigma Chemical (St. Louis, MO). TGR5 ligand
23(S)-mCDCA was provided by Dr. Wendong Huang and Dr.
Donna Yu (City of Hope, Duarte, CA). 23(S)-mCDCA is a
synthetic, highly selective TGR5 agonist used in the previous
work (Pellicciari et al., 2007; Wang et al., 2011). GPBARA [TGR5
Receptor Agonist, 3-(2-Chlorophenyl)-N-(4-chlorophenyl)-N,5-
dimethylisoxazole-4-carboxamide] has been used in the previous
reports (Inoue et al., 2012; Jensen et al., 2013). It was purchased
from BioVision (Milpitas, CA). The pmTGR5 expression vector
was created in our laboratory. The p65 expression vector and
the phRL-TK vector were kindly provided by Xufeng Chen and
Akio Kruoda (both City of Hope, Duarte, CA), respectively.
The NF-κB-dependent reporter (NF-κBx3-LUC) was provided
by Dr. Peter Tontonoz (UCLA, Los Angeles, CA) and Dr. Bruce
Blumberg (UCLA, Los Angeles, CA).
Animals
Eight-week-old wild-type (WT) (C57BL/6J) and TGR5−/−
female mice (on C57BL/6J background; Merck Research
Laboratories, Kenilworth, NJ) were maintained in a pathogen-
free animal facility under a standard 12-h light-dark cycle. In
the preliminary study, we screened the doses of TGR5 ligand
23(S)-mCDCA for in vivo use. It was found that diet containing
10mg/kg of 23(S)-mCDCA was an optimal dose. So mice were
fed a diet containing 10mg of 23(S)-mCDCA/kg diet or standard
rodent chow for 3 days. After that, mice were fasted overnight
and then injected intraperitoneally (i.p.) with a single dose of
LPS (20mg/kg) or phosphate-buffered saline (PBS), followed by
feeding water ad libitum. Six hours after the injection, mice were
killed by CO2 asphyxiation, and the stomach was removed for
further analysis. The animal study proposal was approved by
Beckman Research Institute of City of Hope Institutional Animal
Care and Use Committee (IACUC). All animal experiments were
carried out in accordance with an approved Beckman Research
Institute of City of Hope Institutional Animal Care and Use
Committee (IACUC) protocol.
Cell Culture and Transfection
Gastric cancer cell line SGC7901 was obtained from Institute
of Basic Medical Sciences (IBMS) of Chinese Academy of
Medical Sciences. Cells were grown in complete culture medium
(RPMI-1640 [with L-glutamihe] supplied with 10% (vol/vol)
inactivated fetal calf serum and 1% (vol/vol) antibiotics-
antimycotics). Cultures were fed with fresh medium twice
weekly. For experiments, 6 × 105 SGC7901 cells were seeded in
60-mm culture dishes with complete culture medium. Transient
transfection of SGC7901 cells with TGR5 expression plasmid
was performed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA). Twenty-four hours after transfection, cells were pre-
treated with 23(S)-mCDCA (10µM) or GPBARA (3µM) for
1 day. Then cells were treated with or without LPS or TNF-
α. Following a 6-h incubation for LPS or a 1-h incubation for
TNF-α, cells were harvested for Quantitative Real-Time PCR
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analysis. For protein assay, cells were transfected with TGR5
plasmid and then pre-treated with 23(S)-mCDCA (10µM) or
GPBARA (3µM) for 1 day. Then cells were treated with TNF-
α (10 ng/mL) for 1 h. Finally, cells were collected for total protein
isolation and Western blot assay. For luciferase assay, transient
transfection of SGC7901 cells with the NF-κB reporter plasmid,
phRL-TK, and/or TGR5 expression plasmid was performed.
Twenty-four hours after transfection, cells were pre-treated with
23(S)-mCDCA (10µM), GPBARA (3µM) or vehicle (dimethyl
sulfoxide (DMSO)) for 24 h. Then cells were treated with/without
LPS (20µg/mL) or TNF-α (10 ng/mL). After 6 h of incubation,
cells were harvested and the luciferase activity was determined
using a dual-luciferase reporter assay system in accordance
with the manufacturer’s instructions (Promega, Madison, WI).
Luciferase activities were normalized by co-transfection of
the control thymidine kinase-driven Renilla luciferase plasmid,
phRL-TK. Data are expressed as relative fold activation to that of
non-stimulated (–) sets.
RNA Isolation and Quantitative Real-Time
Polymerase Chain Reaction
Total RNA was extracted from SGC7901 cells using Tri-Reagent
(Molecular Research Center, Inc., Cincinnati, OH). Quantitative
real-time PCR was performed using the Power SYBR Green
PCRMaster Mix protocol (Applied Biosystems, Foster City, CA).
Amplification of β-actin was used as an internal reference. β-
Actin primers were obtained from Ambion, Inc. (Austin, TX).
Quantitative PCR analysis was conducted using the ABI 7300
Sequence Detection System. Primers sequences are available on
request.
Immunoblot Analysis
At indicated time points after treatment, SGC7901 cells were
lysed for 30min with lysis buffer and centrifuged at 12,000
× g at 4◦C for 15min. The samples were resolved by
10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
transferred to nitrocellulose membranes, and blotted using
primary antibodies. The membranes were washed with Tris
Buffered Saline with 0.1%Tween R© 20 (TBST) and then incubated
with anti-rabbit secondary antibody conjugated to horseradish
peroxidase (HRP) (1:5000) (Thermo Scientific, Waltham, MA).
Bands on blots were visualized using Tanon 5200 enhanced
chemiluminescence (ECL) detection system (Tanon, China) and
quantified with a computerized digital imaging system using
Tanon software.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Mice were fed a diet containing 10mg of 23(S)-mCDCA/kg
diet or standard rodent chow for 3 days. After that, mice were
fasted overnight and then injected intraperitoneally (i.p.) with
a single dose of LPS (20mg/kg) or phosphate-buffered saline
(PBS), followed by feeding water ad libitum. Six hours after
the injection, mice were killed, and the stomach was removed
for further protein analysis. Stomach proteins were extracted in
cold PBS and MCP-1 and IP-10 protein levels were determined
using Enzyme-linked Immunosorbent Assay (ELISA) Kit in
accordance with the manufacturer’s instructions (Cloud-Clone
Corp., Houston, TX). For cell culture, the cells were treated with
the indicated reagents. Then proteins were extracted with cold
PBS and determined using ELISA kit in accordance with the
manufacturer’s instructions (Cloud-Clone Corp., Houston, TX).
Statistics
All data represent at least three independent experiments and are
expressed as the mean ± SD. The Two-way analysis of variance
(ANOVA), followed by Bonferroni’s post-hoc test, was performed.
A P < 0.05 was considered significant.
RESULTS
TGR5−/− Mouse Stomach Displays
Elevated Expression of Proinflammatory
Genes
TGR5 is expressed in many organs such as liver, colon, small
intestine, kidney, heart, and stomach. In this work, we found that
TGR5 gene is expressed in stomach slightly higher than that in
liver (Figure 1A). Compared with WT controls, stomach from
TGR5−/− mice had elevated messenger RNA (mRNA) levels of
some proinflammatory genes (Figure 1B). These elevated genes
include interferon-γ (IFN-γ) and inducible nitric oxide synthase
(iNOS).
TGR5 Activation Suppresses Gastric
Inflammation In vivo
If TGR5 is a suppressor of gastric inflammation, TGR5 activation
may suppress some proinflammatory gene expression. We
firstly tested whether ligand-activated TGR5 could inhibit NF-
κB-mediated proinflammatory genes in vivo. TGR5 activation
by 23(S)m-CDCA repressed LPS-induced interferon-inducible
protein 10 (IP-10), iNOS andmonocyte chemoattractant protein-
1 (MCP-1) gene expression in WT stomach, but not TGR5−/−
stomach (Figure 2A). Protein levels of MCP-1 and IP-10 in
WT and TGR5−/− mouse stomach were also tested using
ELISA (Figure 2B). The results show that TGR5 activation
by 23(S)m-CDCA repressed LPS-induced IP-10 and MCP-1
protein expression in WT stomach, but not TGR5−/− stomach
(Figure 2B).
Activation of TGR5 Antagonizes
NF-κB-Mediated Gene Expression in
Gastric Cancer Cells
Our previous work has indicated that TGR5 activation suppresses
NF-κB-mediated gene expression in hepatocytes (Wang et al.,
2011). To investigate whether activation of TGR5 has any effect
on the NF-κB pathway in gastric cells, we tested the influence
of TGR5 agonists on the NF-κB-mediated gene expression in
SGC7901 gastric cancer cells. We firstly tested whether ligand-
activated TGR5 could inhibit NF-κB-mediated gene expression.
In SGC7901 gastric cancer cells, TGR5 ligand 23(S)-mCDCA
suppresses gene expression of IP-10, interleukin (IL)-6, IL-
1β, and MCP-1 mediated by NF-κB while GPBARA treatment
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FIGURE 1 | TGR5 is expressed in stomach and TGR5 −/− mouse stomach displays elevated expression of proinflammatory genes. (A) Levels of TGR5
gene expression in mouse stomach and liver (n = 5). (B) TGR5−/− mouse stomach display elevated expression of proinflammatory genes compared with WT mice
(n = 5). *P < 0.05 vs. WT mice. TGR5KO, TGR5−/− mice.
suppresses gene expression of IP-10, IL-1β, and MCP-1 mediated
by NF-κB (Figure 3A). TGR5 overexpression with the ligands
23(S)-mCDCA or GPBARA treatment repressed gene expression
of IP-10, TNF-α, and MCP-1 mediated by NF-κB (Figure 3B).
Furthermore, TGR5 activation suppressed LPS or TNF-α-
inducedMCP-1 expression (Figure 3C). Some of the results were
also confirmed using ELISA assay to reveal TGR5 activation
suppressedMCP-1 and IP-10 protein expression in gastric cancer
cells (Figure S1 in Supplementary Material).
Activation of TGR5 antagonizes NF-κB
Transcriptional Activity in Gastric Cancer
Cells
Because TGR5 activation by 23(s)m-CDCA and GPBARA
inhibited the expression of NF-κB target genes, we next tested
whether TGR5 activation inhibited NF-κB activity at the level
of gene transcription. We cotransfected SGC7901 cells with
an NF-κB reporter plasmid and the control plasmid phRL-
TK and assessed the effects of GPBARA on the regulation
of NF-κB reporter activity. Treatment with a known NF-
κB pathway activator LPS resulted in 1.5-fold greater NF-κB
reporter activity (Figure 4A). NF-κB activity induced by LPS
was inhibited by GPBARA treatment. Transfection of these
cells with TGR5 inhibited NF-κB activity in the absence of
ligand. However, addition of GPBARA further enhanced this
repression (Figure 4A). Furthermore, we used TNF-α to induce
NF-κB reporter activity. TNF-α resulted in 4.2-fold greater NF-
κB reporter activity (Figures 4B,C). TGR5 overexpression with
23(S)-mCDCA or GPBARA represses TNF-α-induced NF-κB
reporter activity by about 35% (Figure 4B) and 60%, respectively
(Figure 4C). To eliminate the possibility that the compound was
affecting other pathways, we used p65 overexpression to activate
the NF-κB reporter. Overexpression of p65 significantly activated
the NF-κB reporter (Figures 4D,E). NF-κB activity was inhibited
by both TGR5 ligands in the absence of TGR5, but the presence
of TGR5 enhanced this repression.
TGR5 Inhibits IκBα Phosphorylation and
p65 Translocation in Gastric Cancer Cells
Next, we tested the suppression of TGR5 activation on
phosphorylation of IκBα. Compared with the control group,
TNF-α induced phosphorylation of IκBα in SGC7901
cancer cells in a time-dependent manner (Figure S2A in
Supplementary Material). TGR5-transfected SGC7901 cells with
ligand treatment (23(S)-mCDCA) inhibited TNF-α-induced
IκBα phosphorylation by about 65% (Figures 5A,B). The
nuclear translocation of p65 leads to activation of NF-κB.
Overexpression of p65 induced the translocation of p65 in
a time-dependent manner (Figure S2B in Supplementary
Material). TGR5 activation by GPBARA dramatically
suppressed the nuclear translocation of p65 induced by
p65 overexpression in gastric cancer cells (Figures 5C,D).
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FIGURE 2 | TGR5 activation suppresses gastric inflammation in vivo. Mice were fed a diet containing 10mg of TGR5 ligand 23(S)-mCDCA/kg diet or standard
rodent chow for 3 days. After that, mice were fasted overnight and then injected intraperitoneally (i.p.) with a single dose of LPS (20mg/kg) or phosphate-buffered
saline (PBS). Six hours after the injection, mice were sacrificed and the stomach was removed for Real-Time PCR analysis or ELISA analysis. Ligand, 23(S)-mCDCA.
(A) TGR5 ligand 23(S)-mCDCA treatment repressed LPS-induced proinflammatory gene expression in WT, but not TGR5−/− mouse stomach (n = 5–6). *P < 0.05 vs.
the only LPS-treated WT groups. (B) TGR5 ligand 23(S)-mCDCA treatment repressed LPS-induced MCP-1 and IP-10 protein expression in WT, but not TGR5−/−
mouse stomach (n = 5–6). *P < 0.05 vs. the only LPS-treated WT groups.
These results demonstrated that TGR5 activation is able to
suppress IκBα phosphorylation and nuclear translocation
of p65.
DISCUSSION
The known functions of TGR5 in vivo have recently expanded
rapidly from initial roles in regulating energy homeostasis and
metabolic diseases to also participating in inflammation and
carcinogenesis (Cipriani et al., 2011; Pols et al., 2011; Wang
et al., 2011; Cao et al., 2013; Guo et al., 2015). The novel
roles of TGR5 in suppressing inflammation are consistent with
TGR5’s previous roles in defending against diabetes and obesity.
In contrast to its well-established mechanism in regulating
glucose and energy homeostasis, little is known about how
TGR5 functions in gastric inflammation and carcinogenesis.
Our results suggest that one potential role for TGR5 in
protecting against gastric inflammation is by modulating NF-
κB-mediated gastric inflammatory responses. TGR5 activation
strongly suppresses the activity of NF-κB in gastric cell culture
experiments in vitro. This is further supported by animal studies
in vivo.
TGR5 belongs to GPCR family (Wang et al., 2011).
GPCRs play a crucial role in physiology and pathophysiology
in humans through regulating cell migration, proliferation,
differentiation and survival. They are very promising targets
for the development of drugs having therapeutical impact on
many diseases such as chronic inflammation, neurodegeneration,
diabetes, stress, and osteoporosis (Couvineau and Laburthe,
2012; Saxena et al., 2012). Many GPCRs induce NF-κB activation
(Islam et al., 2013), whereas only a few GPCRs inhibit NF-
κB-mediated inflammation (Linden, 2006). Two GPCRs, the
A2A and A2B adenosine receptors, suppress the NF-κB pathway
in a specific gene- and cell-type–dependent manner (Lappas
et al., 2005; Linden, 2006; Sun et al., 2006). Activation of
β2-adrenergic receptor, a subtype of GPCRs, inhibits NF-κB
activity by means of β-arrestin interaction with IκBα. Our
previous data show that TGR5 is a potential suppressor of
NF-κB-dependent inflammatory response through regulating
interaction of β-arrestin2 and IκBα in liver inflammation
(Wang et al., 2011). Other groups also reported that TGR5
activation is associated with different inflammation (Cipriani
et al., 2011; Pols et al., 2011). Here, we found that TGR5
activation inhibited gastric inflammation. Furthermore, it is
found that TGR5 activation antagonizes NF-κB signaling in
gastric cancer cells through inhibiting its transcriptional activity,
phosphorylation of IκBα and p65 translocation. These results
suggest that TGR5 is a suppressor of gastric inflammation
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FIGURE 3 | Activation of TGR5 antagonizes NF-κB-mediated gene expression in gastric cancer cells. (A) TGR5 ligand treatment suppresses
NF-κB-mediated gene expression. 23(S)-mCDCA and GPBARA treated SGC7901 cells for 24 h. (B) TGR5 overexpression with ligand treatment suppresses
NF-κB-mediated gene expression. SGC7901 cells were transfected with the TGR5 expression plasmid or control plasmid. After transfection, cells were treated with
GPBARA (3µM), 23(S)-mCDCA (10µM), or vehicle (DMSO) for 24 h. (C) TGR5 activation suppresses LPS or TNF-α-induced gene expression. SGC7901 cells were
transfected with the TGR5 expression plasmid or control plasmid. After transfection, cells were treated with GPBARA (3µM) or vehicle (DMSO) for 24 h. Then cells
were treated with LPS (10µg/mL) for 6 h or TNF-α (10µg/mL) for 1 h. *P < 0.05, **P < 0.005 vs. the control group. (n = 3).
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FIGURE 4 | Activation of TGR5 antagonizes NF-κB transactivity. (A) TGR5 suppressed NF-κB transactivity induced by LPS. SGC7901 cells were
cotransfected with the NF-κB reporter plasmid (pNF-κB-LUC), phRL-TK, and TGR5 expression plasmid. After transfection, cells were treated with GPBARA
(3µM) or vehicle (DMSO) for 24 h and then treated with LPS (20µg/mL) for 6 h. (B) TGR5 ligand 23(S)-mCDCA suppressed NF-κB transactivity induced by
TNF-α (10µg/mL) for 6 h. (C) TGR5 ligand GPBARA suppressed NF-κB transactivity induced by TNF-α (10µg/mL) for 6 h. (D) TGR5 ligand 23(S)-mCDCA
suppressed NF-κB transactivity induced by p65 overexpression. (E) TGR5 ligand GPBARA suppressed NF-κB transactivity induced by p65 overexpression.
*P < 0.05. RLU, relative luciferase units (n = 3).
through antagonizing NF-κB signaling. It indicates that TGR5
has much broader role than previously thought in suppressing
inflammation.
We noted that activation of TGR5 repressed specific sets of
NF-κB target genes, but not all the target genes in response
to the NF-κB activators that we used in this study (LPS, and
TNF-α). This phenomenon has also been observed for the
function of TGR5 in liver inflammation (Wang et al., 2011).
Similar results obtained indicate the molecular mechanisms
by which TGR5 suppressed NF-κB in liver and gastric
inflammationmay be similar. It would be interesting to define the
mechanism by which TGR5 activation inhibits NF-κB in gastric
cancer cells.
It is noted that transfection of gastric cancer cells with TGR5
inhibited NF-κB activity in the absence of ligand, suggesting
that TGR5 may suppress NF-κB activity without the addition of
exogenous ligand, possibly resulting from the fact that GPCRs
have constitutive activity as previously reported (Tao, 2008; Senft
et al., 2011; Wang et al., 2011).
It has been reported that TGR5 could be a potential target
for the treatment of diabesity and associated metabolic disorders
(Watanabe et al., 2006; Thomas et al., 2008). For example,
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FIGURE 5 | TGR5 inhibits IκBα phosphorylation and p65 translocation in gastric cancer cells. (A) TGR5 overexpression with ligand treatment suppressed
TNF-α-induced phosphorylation of IκBα in SGC7901 cells. Cells were transfected with TGR5 plasmid and then treated with ligand for 24 h. Finally, cells were treated
with TNF-α for 1 h (n = 3) p-IκBα, phosphorylated IκBα; T-IκBα, total IκBα. (B) The data of relative protein levels in (A) are expressed as fold change over the ratio of
p-IκBα to T-IκBα in the control group (lane 1). (C) TGR5 overexpression with ligand treatment suppressed p65 overexpression-induced the translocation of p65 in
SGC7901 cells. Cells were cotransfected with TGR5 and/or p65 plasmids and then were treated with the ligand GPBARA for 24 h. (D) The data of relative protein
levels in (C) are expressed as fold change over the ratio of p65 to Lamin B1 in the control group (lane 1). *P < 0.05.
Watanabe et al. reported that TGR5 activation by bile acids
induces energy expenditure in muscle and brown adipose tissue
(Watanabe et al., 2006). Thomas et al. found that TGR5 activation
improves glucose tolerance and insulin sensitivity in fat-fed
mice (Thomas et al., 2008). These diseases, such as obesity,
insulin resistance, and type 2 diabetes, are also closely associated
with chronic inflammation characterized by abnormal cytokine
production, increased acute-phase reactants, and activation of
a network of inflammatory signaling pathways (Hotamisligil,
2008). Combining with our previous study (Wang et al., 2011),
our results show that TGR5 is a negative modulator of gastric and
liver carcinogenesis probably by antagonizing NF-κB pathway.
Therefore, there is a potential link between anti-cancer and
treatment of obesity and diabetes through TGR5. TGR5 may be
an attractive therapeutic target not only for metabolic disorders
but also for cancer.
In conclusion, our results reveal that TGR5 is a suppressor
of gastric inflammation and TGR5 activation suppresses NF-
κB signaling pathway, indicating that TGR5 ligands have utility
in anti-gastric inflammation. These findings suggest that TGR5
is a potential target for anti-inflammatory drug design, and
its agonist ligands offer possible therapies to prevent and treat
inflammatory gastric diseases.
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